Innovations for Changing the Face of Women’s Reproductive Health Therapeutics

At ObsEva, our passion and expertise in reproductive health and pregnancy therapeutics is helping millions of women worldwide lead healthier and more fulfilling lives.

Significant Unmet Needs in Reproductive Health

Millions of women worldwide suffer from reproductive health conditions that affect their quality of life or ability to conceive and may lead to complications during pregnancy.

Innovation From Conception to Birth and Beyond

ObsEva is advancing a robust pipeline of novel, orally-administered, clinical-stage compounds in the areas of uterine fibroids, endometriosis, assisted reproductive technology, and preterm labor.

Recent Updates

18 Jun 2018

ObsEva Announces Launch of Proposed Follow-on Public Offering

Read more
18 Jun 2018

ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis

Read more
15 Jun 2018

ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018

Read more
01 Jun 2018

ObsEva SA to Seek SIX Share Listing

Read more